Premium
Identification of a melanoma antigen, PRAME, as a BCR/ABL‐inducible gene
Author(s) -
Watari Kiyoshi,
Tojo Arinobu,
Nagamura-Inoue Tokiko,
Nagamura Fumitaka,
Takeshita Akihiro,
Fukushima Toshihiro,
Motoji Toshiko,
Tani Kenzaburo,
Asano Shigetaka
Publication year - 2000
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/s0014-5793(00)01112-1
Subject(s) - myeloid leukemia , k562 cells , breakpoint cluster region , cancer research , abl , microbiology and biotechnology , biology , antigen , transfection , cytotoxic t cell , leukemia , gene , immunology , tyrosine kinase , in vitro , signal transduction , genetics
In order to elucidate molecular events in BCR/ABL‐induced transformation, we adopted a polymerase chain reaction (PCR)‐based technique of differential display and compared mRNA expression in human factor‐dependent cells, TF‐1, with that in factor‐independent cells, ID‐1, which were established from TF‐1 cells by transfection of BCR/ABL. Cloning and sequencing of a gene which was upregulated in ID‐1 cells revealed that the gene was identical to a melanoma antigen, PRAME. Our present study demonstrated that PRAME was markedly expressed in primary leukemic cells with chronic myeloid leukemia (CML) in blastic crisis and Philadelphia (Ph) + ‐acute lymphoblastic leukemia (ALL), in which BCR/ABL played an important role as a pathogenic gene. Moreover, comparison of PRAME expression among CD34 + cells with CML in blastic, accelerated, and chronic phases revealed a higher expression in CML in advanced phases. Thus PRAME was considered to be a good candidate for a marker of Ph + ‐leukemic blast cells as well as a new target antigen of leukemic blast cells that cytotoxic T cells can recognize.